News
PRNAF
0.010
NaN%
--
Alterity Therapeutics Reveals Top Option Holders
TipRanks · 5d ago
Alterity Therapeutics Announces New Securities Quotation
TipRanks · 5d ago
Alterity Therapeutics Issues Caution on Forward-Looking Statements
TipRanks · 5d ago
Weekly Report: what happened at PRNAF last week (0414-0418)?
Weekly Report · 6d ago
Alterity Therapeutics Announces New Options Prospectus to Bolster Financial Strategy
TipRanks · 04/17 04:02
Weekly Report: what happened at PRNAF last week (0407-0411)?
Weekly Report · 04/14 10:52
Promising Phase 2 Results and Technological Integration Justify Buy Rating for Alterity Therapeutics
TipRanks · 04/11 18:25
Alterity Therapeutics reports new data from ATH434 Phase 2 trial at AAN meeting
TipRanks · 04/10 11:45
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
Barchart · 04/10 06:35
Alterity Therapeutics Unveils Promising Phase 2 Study Results for MSA Treatment
TipRanks · 04/10 04:12
Alterity Therapeutics Director Increases Stake Through Share Acquisition
TipRanks · 04/09 06:38
BNY Mellon Reduces Stake in Alterity Therapeutics
TipRanks · 04/07 22:58
Weekly Report: what happened at PRNAF last week (0331-0404)?
Weekly Report · 04/07 10:52
Alterity Therapeutics Completes A$38.79M Placement to Advance Neurodegenerative Disease Treatments
TipRanks · 04/07 02:07
Alterity Therapeutics Issues Over 2.4 Billion Shares in Compliance with Corporations Act
TipRanks · 04/07 01:58
Alterity Therapeutics Announces Quotation of New Securities
TipRanks · 04/07 01:58
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Barchart · 04/03 06:35
Alterity Therapeutics to Present Promising ATH434 Phase 2 Results at Neurology Meeting
TipRanks · 04/03 00:39
Weekly Report: what happened at PRNAF last week (0324-0328)?
Weekly Report · 03/31 11:01
Alterity Therapeutics Secures Shareholder Approval for Key Resolutions
TipRanks · 03/31 03:17
More
Webull provides a variety of real-time PRNAF stock news. You can receive the latest news about Alterity Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PRNAF
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.